News

January 28, 2010

Tufts Center for the Study of Drug Development Launches New Website

BOSTON - Jan. 28, 2010 - The Tufts Center for the Study of Drug Development, the world's leading, independent authority on the nature and pace of pharmaceutical and biotech drug development, today announced the launch of its new website that makes it easier for industry professionals and others to research critical drug development issues.

The website- available at http://csdd.tufts.edu - features one-click navigation that provides easy access to current information on Tufts CSDD research, publications, courses, forums, and press releases.

"Developers, clinical researchers, regulators, policy makers, and service providers working with the industry need reliable, up-to-date information on the factors that shape drug development and the environment for innovation. Our new website supports them by making that information more readily available," said Tufts CSDD Director Kenneth I Kaitin.

New features of the website include:

* Access to a comprehensive bibliography of Tufts CSDD publications, and services available through the Louis Lasagna Library of Drug Development Science and Policy.

* Online registration for Postgraduate and Leadership courses and the Tufts CSDD Executive Forum.

* Online subscriptions to Tufts CSDD Impact Reports and R&D Management Reports.

* Information relating to ongoing multi-company research programs and commissioned projects.

ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

Established in 1976, the Tufts Center for the Study of Drug Development at Tufts University seeks to raise the level of national and international debate on issues relating to new drug and biopharmaceutical product development and regulation. It does that by monitoring and reporting on the development, regulation, and utilization of new drugs and biopharmaceuticals, making that information available through publications, symposia, workshops, and public forums.

Tufts CSDD developed the first, independent assessment and subsequent updates of the cost of developing a new prescription medicine, which is widely referenced by the U.S. Congress, drug developers, regulators, and analysts worldwide. Tufts CSDD also developed the first assessment of the state of the investigator landscape in the U.S. Recently it documented the therapeutic impact of incremental innovation, sometimes referred to as me-too drug development, and the dramatic decline in effective market life for first-in-class pharmaceutical products.

Earlier this month, Tufts CSDD released its annual Outlook report, which noted that the continued success of drug developers will depend on how well they partner with other firms.

--end--

Contact:
Tufts Center for the Study of Drug Development
Peg Hewitt - 617-636-2185
peg.hewitt@tufts.edu

ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED RESEARCH NEWS